Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial 100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse...

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...